Introduction
============

The current Ebola virus outbreak is one of the largest outbreaks of its kind in history and the first in West Africa. By January 14, 2015, a total of 21296 probable and confirmed cases, including 8429 deaths from Ebola virus disease (EVD), had been reported from five countries in West Africa - Guinea, Liberia, Nigeria, Senegal, and Sierra Leone ( <http://apps.who.int/iris/bitstream/10665/148237/2/roadmapsitrep_14Jan2015_eng.pdf?ua=1>). EVD with a high case-fatality rate of 40% and with currently no approved vaccine or therapy, represents a major public health threat.

In response to the current Ebola virus outbreak, the international community has urged for accelerated development of drugs against EVD but also has endorsed the clinical use of unregistered treatments for Ebola ^[@ref-1]^. Conventional time and the money consuming approach of drug development (\> 10 years; \> 2 billions \$) does not meet the current urgent need for anti-Ebola drugs. Repurposing or repositioning of existing drugs could overcome some of these obstacles and help in the rapid discovery and development of therapeutics for EVD, although this approach does not negate the need for some preclinical studies and clinical trials for validation of the proposed indications. Recently, results of two large repurposing screenings of Food and Drug Administration (FDA)-approved drugs have been reported. In the first study, Madrid and co-workers performed *in vitro* and *in vivo* (in mice) screening of 1012 FDA-approved drugs and selected 24 candidate entry inhibitors for Ebola virus ^[@ref-2]^. In the second study, 53 inhibitors of Ebola virus infection with IC ~50~ \< 10 µM and selectivity index SI \> 10-fold have been identified by *in vitro* screening of 2816 FDA-approved drugs ^[@ref-3]^. In the same study, an additional 95 drugs which are active against Ebola virus infection with IC ~50~ \> 10 µM and SI \<10-fold were also reported.

Although *in vitro* and *in vivo* screening for repurposing/repositioning of existing drugs could significantly accelerate discovery of new drugs these approaches are time-consuming and costly for screening of large drug libraries. Recently, we proposed a novel approach for *in silico* screening of molecular libraries for drug candidates ^[@ref-4]--\ [@ref-8]^. This approach, which uses the average quasi valence number (AQVN) and the electron-ion interaction potential (EIIP), parameters determining long-range interaction between biological molecules, might hold a key to overcoming some of these obstacles in experimental screening by significantly reducing the number of compounds which should be *in vitro* and *in vivo* tested ^[@ref-9]^.

Herein, 267 approved and 382 experimental drugs, selected by the EIIP/AQVN-based virtual screening of DrugBank ( <http://www.drugbank.ca>), have been proposed as candidate drugs for treatment of EVD. An open access portal allowing screening of molecular libraries for candidate drugs for treatment of EVD was established.

Material and methods
====================

Molecular libraries
-------------------

For screening of drugs for repurposing to select candidates for Ebola virus entry inhibitors, 1463 approved and 4975 experimental drugs from DrugBank ( <http://www.drugbank.ca>) were screened. For development of the predictive criterion used in this analysis, the learning set ( [Dataset 1](#DS0){ref-type="other"}) encompassing 152 drugs which are selected as inhibitors of Ebola virus infection by *in vitro* and *in vivo* screening of 3828 FDA-approved drugs ^[@ref-2],\ [@ref-3]^, was established. As control data sets 45,010,644 compounds from PubChem ( <http://www.ncbi.nlm.nih.gov/pccompound>) and 49 Ebola virus entry inhibitors collected by data mining of literature and patents, were used. For screening of literature data the NCBI literature database PubMed ( <http://www.ncbi.nlm.nih.gov/pubmed>) was used. For search of patents and patent applications we used the Free Patent Online browser ( <http://www.freepatentsonline.com>).

Drug repurposing screen to identify active compounds that block Ebola entry
---------------------------------------------------------------------------

Specific recognition and targeting between interacting biological molecules at distances \> 5Å are determined by the average AQVN and the EIIP ^[@ref-10]^, which are derived from the general model pseudopotential ^[@ref-11],\ [@ref-12]^. These parameters for organic molecules are determined by the following simple equations ^[@ref-10]^:

$${EIIP = 0.25\frac{Z^{*}\sin\left( 1.04\,\pi\, Z^{*} \right)}{2\pi}}\,\,\,\,\,\,\,(1)$$

Where Z\* is the average quasi-valence number (AQVN) determined by

$${Z^{*} = \frac{1}{N}{\sum\limits_{i = 1}^{m}{n_{i}Z_{i}}}}\,\,\,\,\,\,\,\,\,\,\,\,\,\,\,\,\,(2)$$

where Z ~*i*~ is the valence number of the *i*-th atomic component, n ~*i*~ is the number of atoms of the *i*-th component, *m* is the number of atomic components in the molecule, and N is the total number of atoms. EIIP values calculated according to [equation 1](#e1){ref-type="other"} and [equation 2](#e2){ref-type="other"} are expressed in Rydberg units (Ry).

Among 3300 currently used molecular descriptors, AQVN and EIIP represent the unique physical properties which characterize the long-range interactions between biological molecules ^[@ref-10]^. Small molecules with similar AQVN and EIIP values interact with the common therapeutic target, which allow establish criterions for virtual screening of molecular libraries for compounds with similar therapeutic properties ^[@ref-4]--\ [@ref-9]^. Here we develop the EIIP/AQVN-based criterion for virtual screening of molecular libraries for candidate drugs against Ebola virus infection.

Results and discussion
======================

Previously, analyses of the EIIP/AQVN distribution of 45,010,644 compounds from the PubChem database ( <http://www.ncbi.nlm.nih.gov/pccompound>) revealed that 92.5% of presented compounds are homogenously distributed within EIIP and AQVN intervals (0.00 -- 0.11 Ry) and (2.4 -- 3.3), respectively). This domain of the EIIP/AQVN space, encompassing the majority of known chemical compounds, is referred to as the "basic EIIP/AQVN chemical space" (BCS) ^[@ref-6]^. Analysis of the molecular training set ( [Dataset 1](#DS0){ref-type="other"}), encompassing 152 small molecule inhibitors of Ebola virus infection selected by *in vitro* screening of 3828 FDA approved drugs ^[@ref-2],\ [@ref-3]^, show that 79% of these compounds are placed within AQVN and EIIP region (2.3 -- 2.7) and (0.0829 -- 0.0954 Ry), respectively ("Ebola Virus Infection Inhibitors Space", EVIIS). The AQVN region (2.36 -- 2.54) and the EIIP region (0.0912 -- 0.0924 Ry) form the part of EVIIS which encompasses 55.5% of all drugs from the learning set (core EVIIS, cEVIS). Literature data mining reveals 49 compounds with experimentally proved activity against Ebola virus infection ( [Table 1](#T1){ref-type="table"}) ^[@ref-13]--\ [@ref-29]^. Most of these compounds 47 (95.9%) are placed within EVIIS ( [Table 1](#T1){ref-type="table"}). Of note is that EVIIS and cEVIIS domains contain only 14.6% and 6.5% of compounds from PubChem, respectively. This confirms high specificity of clustering of Ebola virus infection inhibitors within the EIIP/AQVN space. Comparison of distributions of Ebola virus infection inhibitors and compounds from PubMed is given in [Figure 1](#f1){ref-type="fig"}.

###### Small-molecule entry inhibitors for Ebola virus.

  Compound                                    Formula         AQVN    EIIP \[Ry\]   Reference
  ------------------------------------------- --------------- ------- ------------- -----------
  Chloroquine                                 C18H26ClN3      2.375   0.0941        16
  Bafilomycin A1                              C35H58O9        2.471   0.0960        17
  Cytochalasin B                              C29H37NO5       2.611   0.0810        17
  Cytochalasin D                              C30H37NO6       2.676   0.0672        17
  Latruculion A                               C22H31NO5S      2.667   0.0693        17
  Jasplakinolide                              C36H45BrN4O6    2.674   0.0676        18
  Clomiphene                                  C26H28ClNO      2.526   0.0926        18
  Toremifene                                  C26H28ClNO      2.526   0.0926        18
  Chlorpromazine                              C17H19ClN2S     2.600   0.0829        19
  Amiodarone                                  C25H29I2NO3     2.567   0.0880        20
  Dronedarone                                 C31H44N2O5S     2.578   0.0864        20
  Verapamil                                   C27H38N2O4      2.535   0.0917        20
  Clomiphene                                  C26H28ClNO      2.526   0.0926        21
  AY-9944                                     C22H28Cl2N2     2.370   0.0938        21
  Ro 48-8071                                  C23H27BrFNO2    2.505   0.0940        21
  U18666A                                     C25H41NO2       2.290   0.0849        21
  Terconazole                                 C26H31Cl2N5O3   2.687   0.0644        21
  Triparanol                                  C27H32ClNO2     2.508   0.0941        21
  Impramine                                   C19H24N2        2.444   0.0964        22
  3.47                                        C34H43N3O5      2.635   0.0763        23
  Cytochalasin B                              C29H37NO5       2.611   0.0810        24
  Cytochalasin D                              C30H37NO6       2.676   0.0672        24
  Latrunculin A                               C22H31NO5S      2.667   0.0693        24
  Jasplakinolide                              C36H45BrN4O6    2.674   0.0676        24
  NSC62914                                    C31H40O3        2.460   0.0962        25
  Compound 1                                  C30H38N6O2      2.632   0.0770        26
  Compound 2                                  C32H46N6        2.429   0.0963        26
  Compound 3                                  C28H34N6O2      2.686   0.0635        26
  Compound 5                                  C42H58N10O6     2.690   0.0635        27
  Compound 8a                                 C17H23N3O3      2.695   0.0621        27
  Compound 8b                                 C17H23N3O3      2.695   0.0621        27
  Compound 8y                                 C16H20BrNO2     2.610   0.0812        27
  Compound 15h                                C15H20JN5O      2.667   0.0693        27
  Compound 15k                                C15H128Br3N5O   2.667   0.0693        27
  Retinazone                                  C38H56Na3N5S2   2.385   0.0947        28
  Compound 7                                  C17H12F4N2      2.467   0.0647        29
  Brincidofovir [\*](#n1){ref-type="other"}   C27H52N3O7P     2.467   0.0961        30
  Hit compound 3                              C25H35N3O2      2.494   0.0950        31
  Hit compound 3.1                            C21H24ClN3O2    2.667   0.0693        31
  Hit compound 3.2                            C20H29N3O2      2.518   0.0933        31
  Hit compound 3.3                            C30H35N3O2      2.556   0.0894        31
  Hit compound 3.4                            C25H32N4O3      2.656   0.0717        31
  Hit compound 3.5                            C20H23N3O2      2.708   0.0587        31
  Hit compound 3.6                            C25H33N3O2      2.540   0.09913       31
  Hit compound 3.7                            C22H27N3O3      2.691   0.0633        31
  Hit compound 3.18                           C26H37N3O2      2.471   0.0471        31
  Hit compound 3.48                           C34H43N3O5      2.635   0.0763        31
  Hit compound 3.105                          C34H40N6O2      2.658   0.0712        31
  NSC 62914                                   C31H39O3        2.480   0.0957        32

\*Experimental drug applied for treatment of Ebola patients in Liberia ( <http://www.ox.ac.uk/news/2014-11-13-oxford-lead-trial-experimental-drug-ebola-patients>)

![Distribution of compounds according to their average quasivalence number (AQVN) and electron-ion interaction potential (EIIP) values.\
( **A**) 45010644 compounds from the PubChem database ( <http://www.ncbi.nlm.nih.gov/pccompound>); ( **B**) FDA-approved drugs which are active against Ebola virus infection ( [Dataset 1](#DS0){ref-type="other"}) ^[@ref-2],\ [@ref-3]^; ( **C**) Entry inhibitors of Ebola virus ( [Table 1](#T1){ref-type="table"}).](f1000research-4-6544-g0000){#f1}
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It was shown that Ebola virus glycoprotein (GP)-mediated entry and infection is subordinated with a membrane-trafficking event that translocates a GP binding partner to the cell surface, which depends on microtubules ^[@ref-30],\ [@ref-31]^. Consistently, microtubule inhibitors which block this trafficking process could decrease infection without interfering with the direct binding and translocation of the Ebola virus into cells. AQVN and EIIP values of microtubule modulators and transcription inhibitors with reported anti-Ebola virus activity are given in [Table 2](#T2){ref-type="table"}. As can be seen, all these compounds, which do not directly affect binding and internalization of Ebola virus, are located outside of EVIIS. This additionally confirms the specificity of the EVIS domain.

###### Viral transcription inhibitors and microtubule modulators with anti-Ebola virus activity.

  Compound                             Formula        AQVN    EIIP \[Ry\]
  ------------------------------------ -------------- ------- -------------
  **Viral transcription inhibitors**                          
  BCX4430                              C11H15N5O3     3.000   0.0439
  Favipiravir                          C5H4FN3O2      3.467   0.1304
  C-c3Ado                              C12H16N4O3     2.914   0.0112
  c3Nep                                C12H14N4O3     3.030   0.0552
  "D-like" 1'-6'-isoneplanocin         C11H12N5O3     3.194   0.1076
  "L-like" 1'-6'-isoneplanocin         C11H12N5O3     3.194   0.1076
  CMLDBU3402                           C30H26BrN3O7   3.045   0.1343
  **Microtubule modulators**                                  
  Vinblastine                          C13H8Cl2N2O4   3.310   0.0130
  Vinorelbine                          C45H54N4O8     2.721   0.0552
  Vincristine                          C46H56N4O10    2.759   0.0439
  Colchicine                           C22H25NO6      2.852   0.0121
  Nocodazole                           C14H11N3O3S    3.312   0.1298
  Mebendazole                          C16H13N3O3     3.143   0.0934
  Albendazole                          C12H15N3O2S    2.909   0.0092

In further analysis we used EVIIS as a filter for virtual screening for candidate Ebola virus infection inhibitors. In [Dataset 2](#DS1){ref-type="other"} 622 approved and 1089 experimental drugs in [Dataset 3](#DS2){ref-type="other"} selected by EVIIS screening of 6532 drugs from DrugBank are reported. Using cEVIIS, we located 267 approved and 382 experimental drugs. This small molecular library represents a source of candidate drugs for treatment of Ebola virus disease (EVD), which can be further experimentally tested.
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Madrid and co-workers selected 24 drugs by *in vitro* screening of 1012 FDA-approved drugs, which are effective against Ebola virus infection ^[@ref-2]^. They also showed that among these compounds, four antimalarial drugs (chloroquine, hydroxychloroquine, amodiaquine and aminoquinoline-13) also are effective against Ebola virus infection *in vivo* ^[@ref-2]^. Among 53 compounds which effectively inhibit Ebola virus infection *in vitro*, which Kouznetsova and co-workers selected from 2816 approved drugs, are also three anti-malarial drugs (mefloquione, chloroquine, amodiaquine) ^[@ref-3]^. It was also suggested that application of chloroquine for prevention of virus transmission should be considered because this compound significantly inhibits Ebola virus infection ^[@ref-13]^. Our analysis showed that 15 of 22 approved ant-malarial drugs ( <http://en.wikipedia.org/wiki/Antimalarial_medication>) are located in EVIIS ( [Table 3](#T3){ref-type="table"}). Six 2-alkylquinolines have been also included in this study. This chemical series is promising as some derivatives exhibited antiviral activity such as 2PQ, and 2QQ ^[@ref-32],\ [@ref-33]^ antimalarial activity such as 2PQ and 2PentQ2 ^[@ref-34]^, antileishmanial activity such as 2PQ ^[@ref-35],\ [@ref-36]^ and neurotrophin-like activity on dopaminergic neurons such as 2QI15 ^[@ref-37]^. These compounds exhibit some advantages in regard to their chemical synthesis with few steps and good yields as well as their chemical stability in tropical conditions of storage. Their combined effects against virus and Leishmania parasites suggested they could be an advantage for the treatment of Leishmania/HIV co-infections and they were considered as attractive enough to enter the pipeline of DNDi on 2010.

All these data strongly suggest that this class of drugs should be further investigated as a promising source of therapeutics for treatment of EVD. Anti-malarial drugs with dual activity should be of special interest because malaria represents the highest health-related disease in African countries with EVD.

Among 3828 FDA-approved drugs screened for anti-Ebola activity were six antibiotics which inhibit Ebola virus infection (azthromycin, erythromycin, spiramycin, dirithromycin, maduramicin, charitromycin) ^[@ref-2],\ [@ref-3]^. All these antibiotics are within EVIIS and four of them are in cEVIIS. Analysis of 184 approved antibiotics ( [Dataset 4](#DS3){ref-type="other"}) showed that only 32 (17.4%) have AQVN and EIIP values in EVIIS, and that 11 of them are located within cEVIIS. Previously we reported domains of AQVN and EIIP which characterize different classes of antibiotics ( [Table 4](#T4){ref-type="table"}) ^[@ref-6]^. According to these data, among antibiotics some macrolides, pleuromutilins and aminoglycosides have the highest chance for inhibition of Ebola virus infection. Of note is that five of six antibiotics with experimentally proved activity against Ebola virus infection (azthromycin, erythromycin, spiramycin, dirithromycin, charitromycin) are macrolides. Antibiotics representing candidate Ebola virus infection inhibitors selected by EIIP/AQVN criterion are given in [Table 5](#T5){ref-type="table"}.

###### Approved anti-malarial drugs selected as candidate drugs for EVD.

  Compound           Formula         AQVN    EIIP \[Ry\]
  ------------------ --------------- ------- -------------
  Quinine            C20H24N2O2      2.625   0.0784
  Chloroquinine      C18H26ClN3      2.375   0.0941
  Amodiquinine       C20H22ClN3O     2.638   0.0756
  Proguanil          C11H16ClN5      2.606   0.0819
  Mefloquine         C17H16F6N2O     2.524   0.0928
  Primaquine         C15H21NO3       2.600   0.0829
  Halofantrine       C26H30Cl2F3NO   2.381   0.0945
  Clindamycin        C18H33ClN2O5S   2.533   0.0919
  Artemether         C16H26O5        2.553   0.0897
  Piperaquine        C29H32Cl2N6     2.609   0.0814
  Artemotil          C17H28O5        2.520   0.0931
  Dihydroartemisin   C15H24O5        2.591   0.0844
  Quinidine          C20H24N2O2      2.625   0.0784
  Cinchonidine       C19H22N2O       2.591   0.0844
  Artemisin          C15H22O5        2.667   0.0693

###### AQVN and EIIP range of different antibiotics classes ^[@ref-6]^.

  Antibiotic class       AQVN            EIIP \[Ry\]
  ---------------------- --------------- ---------------
  Penicillins            2.975 - 3.180   0.035 - 0.124
  Cephalosporins         3.071 - 3.473   0.070 - 0.130
  Carbapenems & Penems   2.973 - 3.059   0.022 - 0.066
  Monobactams            3.166 - 3.581   0.100 - 0.134
  Quinolines             2.760 - 3.060   0.003 - 0.065
  Aminoglycosides        2.552 - 2.820   0.024 - 0.084
  Tetracyclines          2.933 - 3.111   0.018 - 0.084
  Macrolides             2.467 - 2.630   0.077 - 0.096
  Pleuromutilins         2.395 - 2.473   0.095 - 0.096
  Nitrofurans            3.652 - 3.826   0.010 - 0.086
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Previous, we determined AQVN and EIIP domains characterizing different classes of anti-HIV drugs ^[@ref-4]--\ [@ref-9]^. As can be seen in [Table 6](#T6){ref-type="table"}, the EIIP/AQVN domain of CCR5 HIV entry inhibitors is within EVIIS, and domains of CXCR4 HIV entry inhibitors and HIV protease inhibitors partially overlaps EVIIS. The EIIP/AQVN domains of other classes of anti-HIV agents are located outside EVIIS. This indicates that some HIV entry inhibitors and HIV protease inhibitors could also be effective drugs against Ebola virus infection.

###### Antibiotics selected as candidate drugs for EVD.

  Antibiotics      Formula                     AQVN    EIIP \[Ry\]
  ---------------- --------------------------- ------- -------------
  Tiamulin         C ~28~H ~47~NO ~4~S         2.395   0.095
  Retapamulin      C ~30~H ~47~NO ~4~S         2.434   0.096
  Valnemulin       C ~31~H ~52~N ~2~O ~5~S     2.440   0.096
  Azithromycin     C ~38~H ~72~N ~2~O ~12~     2.468   0.096
  BC-3205          C ~32~H ~51~N ~2~O ~5~S     2.472   0.096
  Dirithromycin    C ~42~H ~78~N ~2~O ~14~     2.500   0.095
  Clarithromycin   C ~38~H ~69~NO ~13~         2.512   0.094
  Surfactin        C ~53~H ~93~N ~7~O ~13~     2.518   0.093
  Erythromycin     C ~37~H ~67~NO ~13~         2.525   0.093
  Clindamycin      C ~18~H ~33~ClN ~2~O ~5~S   2.533   0.092
  Roxithromycin    C ~41~H ~76~N ~2~O ~15~     2.537   0.092
  Oleandomycin     C ~35~H ~61~NO ~12~         2.550   0.090
  Gentamicin       C ~21~H ~43~N ~5~O ~7~      2.553   0.090
  Spiramycin       C ~43~H ~74~N ~2~O ~14~     2.556   0.089
  Mupirocin        C ~26~H ~44~O ~9~           2.557   0.089
  Lincomycin       C ~18~H ~34~N ~2~O ~6~S     2.590   0.085
  Netilmicin       C ~21~H ~41~N ~5~O ~7~      2.595   0.084
  Astromicin       C ~17~H ~35~N ~5~O ~6~      2.603   0.082
  Tylosin          C ~46~H ~77~NO ~17~         2.610   0.081
  Kitasamycin      C ~35~H ~59~NO ~13~         2.611   0.081
  Josamycin        C ~42~H ~69~NO ~15~         2.614   0.080
  Telithromycin    C ~43~H ~65~N ~5~O ~10~     2.618   0.080
  Telithromycin    C ~43~H ~65~N ~5~O ~10~     2.618   0.080
  Verdamicin       C ~20~H ~39~N ~5~O ~7~      2.620   0.080
  Midecamycin      C ~41~H ~67~NO ~15~         2.629   0.078
  Troleandomycin   C ~41~H ~67~NO ~15~         2.629   0.078
  Sisomicin        C ~19~H ~37~N ~5~O ~7~      2.647   0.074
  Cethromycin      C ~42~H ~59~N ~3~O ~10~     2.649   0.073
  Carbomycin A     C ~42~H ~67~NO ~16~         2.667   0.069
  Dibekacin        C ~18~H ~37~N ~5~O ~8~      2.676   0.067
  Echinocandin B   C ~52~H ~81~N ~7~O ~16~     2.692   0.063
  Rifabutin        C ~46~H ~62~N ~4~O ~11~     2.699   0.061

###### AQVN and EIIP range of anti-HIV drugs ^[@ref-6]^.

  Target                AQVN          EIIP \[Ry\]
  --------------------- ------------- ---------------
  CXCR4                 2.16 - 2.53   0.062 - 0.096
  CCR5                  2.42 - 2.63   0.079 - 0.099
  PI                    2.61 - 2.78   0.040 - 0.080
  NRTI/NtRTI            2.92 - 3.20   0.040 - 0.100
  INI                   3.00 - 3.20   0.044 - 0.116
  Anti-HIV flavonoids   3.34 - 3.59   0.110 - 0.135

In conclusion, the presented results show that the EIIP/AQVN criterion can be used as an efficient filter in virtual screening of molecular libraries for candidate inhibitors of Ebola virus infection. Approved ( [Dataset 2](#DS1){ref-type="other"}) and experimental drugs ( [Dataset 3](#DS2){ref-type="other"}), anti-malarial drugs ( [Table 3](#T3){ref-type="table"}) and antibiotics ( [Table 5](#T5){ref-type="table"}) selected by this criterion represents a valuable source of candidate therapeutics for treatment of EVD, some of which are already approved by FDA for treatment of other diseases which can be repurposed for use in EVD. We hope that these data, obtained by an *in silico* drug repurposing screen, will accelerate discovery of drugs for treatment of EVD, which are necessary in this ongoing emergency situation caused by the current unprecedented Ebola virus outbreak. To enable other researchers working on online EIIP/AQVN-based screening of different sources of small molecules for candidate Ebola drugs, we established an open web server ( <http://www.biomedconsulting.info/ebola_screen.php>).

Data availability
=================

The virtual screen for candidate inhibitors of EBOLA virus infection web tool is available at: <http://www.biomedconsulting.info/tools/ebolascreen.php>. An archived version can be accessed at: <http://www.webcitation.org/6Vxtuojgx> ^[@ref-38]^

F1000Research: Dataset 1. FDA-approved drugs which are active against Ebola virus infection ^[@ref-2],\ [@ref-3]^, [10.5256/f1000research.6110.d42876](http://dx.doi.org/10.5256/f1000research.6110.d42876) ^[@ref-39]^

F1000Research: Dataset 2. Approved and experimental drugs selected as candidate for treatment of EVD, [10.5256/f1000research.6110.d42877](http://dx.doi.org/10.5256/f1000research.6110.d42877) ^[@ref-40]^

F1000Research: Dataset 3. Experimental drugs selected as candidate for treatment of EVD, [10.5256/f1000research.6110.d42878](http://dx.doi.org/10.5256/f1000research.6110.d42878) ^[@ref-41]^

F1000Research: Dataset 4. Approved antibiotics screened for candidate anti-Ebola drugs, [10.5256/f1000research.6110.d42879](http://dx.doi.org/10.5256/f1000research.6110.d42879) ^[@ref-42]^
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To identify drug candidates against Ebola virus infections is surely an urgent need, especially in light of recent virus outbreaks registered mostly in Africa. In this respect, Velijkovic\'s  article is presented in a timely manner and offers a fast and reliable opportunity to screen among large databases to reposition old drugs against Ebola.

The experimental design relies on a consolidated methodology, developed by some of the authors and successfully applied in multiple projects. Overall, the manuscript is clear and few minor editing would be necessary, in my personal opinion, to improve its consistency.

In Materials and Methods, a dataset of 152 drugs that counteract Ebola virus *in vitro* and *in vivo* has been selected as training set. However, it seems that an inconsistency does exist within this number. As authors have reported, these anti-Ebola drugs have been identified by Madrid (24 molecules) and Kouznetsova (53 molecules and 95 weaker drugs). Accordingly, the total number of FDA-approved drugs identified in these studies is 172. Why authors used a smaller set of 152? Is there any structural redundancy? A clarification of this discrepancy would improve the reproducibility of the work.

Finally, if I understood properly authors have selected more than 500 molecules (including FDA-approved and experimental drugs) as anti-Ebola candidates by means of *in silico*screening and suggest that further *in vitro/in vivo* tests should be performed on these molecules. In my opinion, this number is still too large for enabling efficient and fast *in vitro*and/or *in vivo* assays. Experimental testing of this set would require significant efforts. Just for comparison, the number of candidates selected in silico by authors is about half of those selected by Madrid by means of HTS (ref 2). Is there a way to prioritize small molecules by using the EIIP/AQVN-based approach, and to provide a lower number of compounds to be submitted to experimental evaluation? Authors should comment on this point, because the advantage of using the EIIP/AQVN-based screening in silico appears to be limited in the current version of the manuscript.
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This manuscript deals with the *in silico* analysis of molecules for their activity against Ebola Virus (EBV). They started from a reference library of compounds who have previously demonstrated *in vitro* and/or *in vivo*activity against EBV and analyzed these compounds by the determination of their EIIP and AQVN. With these data, they scanned a larger collection of compounds with unknown activity against EBV and selected possible candidates to test for their activity *in vitro*and/or *in vivo*. This is a straight forward manuscript however it may be better structured. The part of the M&M dealing with the EIIP and AQVN is more appropriate to go into the introduction since this is background information of the calculation. For clarity of the manuscript is also better to separate the results section as it is difficult to follow now. Start with the analysis of the compounds with known activity, the two datasets, and then proceed with results from the unknown dataset. Then in the discussion, the different products of interest may be evaluated. This will largely increase the readability. Upon the antibiotics, it would be good to elaborate a bit on how they work on EBV, since common sense tells that antibiotics do not work on viruses. A better explanation on how these products may interact and inhibit/kill EBV would also be good.
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